Ursula A. Matulonis, MD, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.
Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer. The results of the study demonstrated an improvement in the median progression-free survival for patients who received niraparib versus placebo.
Breast Cancer Survivors Find Success With Pregnancy After Treatment
May 24th 2024A study offers promising news for young women with early-stage breast cancer who want to have children after treatment, showing that 73% of breast cancer survivors who attempted pregnancy were successful.
Read More